Markets:

Overview

News

Currencies

International

Treasuries

Palvella Therapeutics, Inc. - Common Stock (NQ:PVLA)

98.90 -2.13 (-2.11%)

Streaming Delayed Price Updated: 9:30 AM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Palvella Therapeutics, Inc. - Common Stock

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

January 05, 2026

Via Chartmill

Palvella Therapeutics Inc (NASDAQ:PVLA) Reports Q3 2025 Earnings Miss, Highlights Key Clinical Milestones ↗

November 11, 2025

Palvella Therapeutics reported a wider Q3 2025 loss, missing EPS estimates. Investors focus on its strong cash position and upcoming clinical trial data for its rare disease pipeline.

Via Chartmill

Topics Earnings

Palvella Therapeutics Inc (NASDAQ:PVLA) Reports Wider Q2 2025 Loss, Stock Drops 13% Despite Clinical Progress ↗

August 14, 2025

Palvella Therapeutics (PVLA) reported a Q2 2025 net loss of $0.86 per share, missing estimates. Revenue was $0.0 as expected, with $70.4M cash on hand. Stock fell 13% pre-market despite clinical...

Via Chartmill

Palvella Posts Cash Gain and Trial Wins ↗

August 14, 2025

Via The Motley Fool

Topics Intellectual Property

Earnings Scheduled For August 14, 2025 ↗

August 14, 2025

Via Benzinga

Earnings Scheduled For November 11, 2025 ↗

November 11, 2025

Via Benzinga

This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

August 06, 2025

Via Benzinga

This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

August 04, 2025

Via Benzinga

Earnings Scheduled For May 15, 2025 ↗

May 15, 2025

Via Benzinga

This Couchbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

April 09, 2025

Via Benzinga

Earnings Scheduled For March 31, 2025 ↗

March 31, 2025

Via Benzinga

Pavella - Undiscovered Biotechnology Stock ↗

March 12, 2025

The company focuses on developing therapies for rare genetic skin diseases, with its lead product QTORIN rapamycin in advanced clinical trials.

Via Talk Markets

Topics Stocks / Equities

This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

February 20, 2025

Via Benzinga

This Intuitive Machines Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday ↗

February 05, 2025

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.